The Efficacy of Lidocaine Spray in Pain Relief during Outpatient-Based Endometrial Sampling: A Randomized Placebo-Controlled Trial

Table 1

Demographic data of participants.

	placebo group	Lidocaine group	p-value
	(N = 70)	(N = 70)
Age (year)	48.28 ± 7.48	47.41 ± 7.59	0.495
Body weight (kg)	62.84 ± 15.65	65.34 ± 19.52	0.405
Height (cm)	157.38 ± 5.92	157.28 ± 6.99	0.1
BMI (kg/m^2)	25.31 ± 5.84	26.26 ± 6.9	0.384
Parity	1.72 ± 1.17	1.85 ± 1.31	0.543
Normal labor	1.08 ± 1.01	0.98 ± 1.14	0.586
Abortion	0.44 ± 0.6	0.38 ± 0.72	0.614
Age of last child(year)	12.88 ± 11.38	15.12 ± 10.71	0.232
Duration (minute)	6.94 ± 3.34	6.47 ± 2.4	0.34
No UD	43(61.4)	33(47.1)	0.09
DM	4(5.7)	6(8.6)	0.745
Heart	2(2.59)	0	0.496
HT	11(15.7)	15(21.4)	0.385
Anemia	1(1.4)	2(2.9)	1
Hormonal used	7(10)	15(21.4)	0.063
Hx of STD	4(5.7)	5(7.1)	1
Hx of cervical dilatation	21(30)	24(34.3)	0.587
Menopause	19(27.1)	20(28.6)	0.85

Mean ± SD (standard deviation), n (%), BMI: body mass index, UD: underlying disease, DM: diabetes mellitus, HT: hypertension, Hx: history, and STD: sexually transmitted diseases.